Dr Joanna Kedra
Country: France
Joanna is a rheumatologist at Sorbonne University and the Department of Rheumatology at Pitié-Salpêtrière Hospital in Paris, France. Her research focuses on the benefit-risk balance of targeted therapies in rheumatoid arthritis using large real-world healthcare databases. She has contributed to the development and updating of recommendations for both the French Society of Rheumatology (SFR) and EULAR. Joanna is a member of the EMEUNET Newsletter Sub-Committee.
| Poster 0441| Sunday, 08.11.2026 10:30–12:30 Session: Poster Session A: Rheumatoid Arthritis – Treatment Presenting author: R. Kasiraj (USA) Title: Cardiovascular Outcomes of Upadacitinib/Baricitinib Versus Tofacitinib in Rheumatoid Arthritis: A Propensity-Matched Retrospective Study  In this propensity-matched real-world study of >27,000 rheumatoid arthritis patients, tofacitinib was associated with significantly higher all-cause mortality (RR 1.78, 95% CI 1.63-1.95) and composite MACE (RR 2.41, 95% CI 2.11-2.75) compared to upadacitinib/ baricitinib. Tofacitinib also showed consistently higher risks for myocardial infarction, stroke, heart failure, and thromboembolic events. These observational findings suggest lower cardiovascular risk with upadacitinib/baricitinib than with tofacitinib in this cohort; they do not establish causality. |
| Poster 0467| Sunday, 08.11.2026 10:30–12:30 Session: Poster Session A: Rheumatoid Arthritis – Treatment Presenting author: L. Kawka (France) Title: Safety and effectiveness of 265 combinations of targeted therapies in immune mediated inflammatory diseases : data from the COMBATT registry This real-world study evaluated combination targeted therapies (cTT) in 204 patients with immune-mediated inflammatory diseases (IMIDs). cTT was mainly initiated for single refractory IMIDs (48.0%) or coexisting IMIDs (51.9%). Treatment was effective or partially effective in 62.3% of single refractory cases with an acceptable safety profile (severe infections incidence: 5.2/100 patient-years), though these results have to be confirmed by larger, longer studies. |
| Oral 1898| Monday, 09.11.2026 15:00 Session: Rheumatoid Arthritis – Treatment Presenting author: D. Yesho (USA) Title: GLP-1 receptor agonist for primary prevention of DMARD-associated malignancy in patients with Rheumatoid Arthritis taking DMARDs: A multi-center real-world analysis In this propensity-matched real-world study of 24,142 rheumatoid arthritis patients on DMARDs, GLP-1 receptor agonists (GLP-1 RAs) were associated with a significant reduction in malignancy risk. Over a 5-year follow-up, GLP-1 RA use was associated with a 38% risk reduction in incident lung cancer and a 52% risk reduction in non-Hodgkin lymphoma. These results suggest a potential protective role for GLP-1 RAs against DMARD-associated malignancies, possibly through anti-inflammatory, immunomodulatory, and direct anti-proliferative mechanisms. |
| Oral 1899| Monday, 09.11.2026 15:15 Session: Rheumatoid Arthritis – Treatment Presenting author: G. Valenzuela (USA) Title: AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells, in Combination with Rituximab Generate Robust Efficacy Responses Comparable with Autologous CAR T in 34 Patients with Rheumatologic Diseases In a Phase 2a basket study of 34 patients with treatment-refractory autoimmune diseases (rheumatoid arthritis, Sjögren’s disease, systemic sclerosis), outpatient AB-101 (NK cells) plus rituximab achieved deep B-cell depletion and robust, sustained clinical improvements at 6 months. This combination delivered CAR-T-like efficacy without severe toxicities such as CRS, ICANS, or GvHD. These results highlight a promising, convenient outpatient therapy for refractory rheumatologic conditions. |
| Oral 1903| Monday, 09.11.2026 16:15 Session: Rheumatoid Arthritis – Treatment Presenting author: C. Immediato Daien (France) Title: Dietary Fibre Supplementation improves Rheumatoid Arthritis and Th17/Treg Balance: Results from the SUPERFIBRES Randomized Controlled Trial. In a randomized controlled trial of 48 rheumatoid arthritis patients on DMARDs, 30-day inulin fibre supplementation significantly increased EULAR response rates (OR 4.65, 95% CI 1.15-18.9) compared to placebo. Fibre intake also reduced circulating Th17 cells and improved the Th17/Treg immune balance, while inducing distinct gut microbiota shifts. These findings suggest dietary fibre is a safe, low-cost adjunct to enhance methotrexate efficacy in RA. |
| Poste 2405| Tuesday, 10.11.2026 10:30–12:30 Session: Poster Session C: Rheumatoid Arthritis – Treatment Presenting author: M. Movahedi (Canada) Title: Oral Glucocorticoid Use and Discontinuation Among JAK inhibitors and Biologic DMARDs in Rheumatoid Arthritis: A Canadian Retrospective Cohort Study In this real-world study of rheumatoid arthritis patients initiating targeted therapies, oral glucocorticoid (GC) use declined over 36 months across all drug classes (JAKi, TNFi, non-TNFi bDMARDs). JAKi demonstrated comparable GC-sparing effectiveness to bDMARDs, with no significant differences in GC discontinuation rates. However, JAKi users achieved numerically lower GC exposure and significantly lower daily doses at 36 months compared to TNFi users. |
| Oral (Plenary) 2807| Tuesday, 10.11.2026 11:00 Session: Plenary III Presenting author: E. Roberts (USA) Title: Equivalent effectiveness but decreased persistence in patients switched to biosimilar infliximab: evidence from real world data In this real-world study of rheumatoid arthritis patients from the RISE registry, switching from originator to biosimilar infliximab maintained equivalent disease control, with no increase in flares or uncontrolled disease. However, switchers demonstrated significantly lower treatment persistence over one year compared to non-switchers (274.6 vs 311 days, p < 0.01). These findings support comparable clinical effectiveness but lower persistence after switching; the reasons for this difference require further study. |